ECSP077281A - CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME - Google Patents

CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME

Info

Publication number
ECSP077281A
ECSP077281A EC2007007281A ECSP077281A ECSP077281A EC SP077281 A ECSP077281 A EC SP077281A EC 2007007281 A EC2007007281 A EC 2007007281A EC SP077281 A ECSP077281 A EC SP077281A EC SP077281 A ECSP077281 A EC SP077281A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
glicerol
ramified
conjugates
Prior art date
Application number
EC2007007281A
Other languages
Spanish (es)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of ECSP077281A publication Critical patent/ECSP077281A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la PEGlilación de la hormona del crecimiento humano (hGh) usando un PEG ramificado con glicerol. La presente invención también se refiere a procesos para la PEGilación de hGH. Además, la presente invención se refiere a composiciones farmacéuticos que comprenden la hGH PEGilada. Otra realización es el uso de hGH PEGilada para el tratamiento de trastornos del crecimiento y del desarrollo.The present invention relates to PEGylation of human growth hormone (hGh) using a PEG branched with glycerol. The present invention also relates to processes for the PEGylation of hGH. In addition, the present invention relates to pharmaceutical compositions comprising PEGylated hGH. Another embodiment is the use of PEGylated hGH for the treatment of growth and development disorders.

EC2007007281A 2004-08-31 2007-02-27 CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME ECSP077281A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
ECSP077281A true ECSP077281A (en) 2007-03-29

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007281A ECSP077281A (en) 2004-08-31 2007-02-27 CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297889T3 (en) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CA2359345A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101448525A (en) * 2006-05-12 2009-06-03 东亚制药株式会社 Polyethylene glycol-interferon alpha conjugate
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
CA2731546C (en) * 2008-07-23 2013-11-19 Hanmi Holdings Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR072850A1 (en) 2008-07-31 2010-09-22 Pharmaessentia Corp PEPTIDO-POLYMER CONJUGATES
SI2340271T1 (en) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Polymer-bioactive agent conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
CA2949337C (en) * 2008-10-10 2019-03-26 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
KR102540109B1 (en) 2014-11-06 2023-06-02 파마에센시아 코퍼레이션 Dosage Regimen for PEGylated Interferon
HRP20220041T1 (en) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Process for providing pegylated protein composition
HRP20220388T1 (en) * 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Process for providing pegylated protein composition
KR102523239B1 (en) * 2017-12-29 2023-04-18 에프. 호프만-라 로슈 아게 Methods for Providing Pegylated Protein Compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
ES2297889T3 (en) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR0214451A (en) * 2001-11-20 2006-05-30 Pharmacia Corp chemically modified human growth hormone conjugates
KR20050093856A (en) * 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 Water-soluble polymer alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
EP1581260B1 (en) * 2002-12-31 2014-09-17 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
PT2644206T (en) * 2003-05-23 2019-07-10 Nektar Therapeutics Peg derivatives containing two peg chains

Also Published As

Publication number Publication date
ZA200701802B (en) 2008-08-27
TW200621291A (en) 2006-07-01
NO20071322L (en) 2007-05-29
CR8942A (en) 2007-08-16
UY29088A1 (en) 2006-03-31
AR050851A1 (en) 2006-11-29
AP2007003919A0 (en) 2007-02-28
KR20070042567A (en) 2007-04-23
TNSN07078A1 (en) 2008-06-02
GT200500235A (en) 2006-03-21
CN101010105A (en) 2007-08-01
MA28908B1 (en) 2007-10-01
IL181085A0 (en) 2007-07-04
MX2007002441A (en) 2007-05-04
AU2005278903A1 (en) 2006-03-09
WO2006024953A2 (en) 2006-03-09
NL1029828A1 (en) 2006-03-01
JP2008511610A (en) 2008-04-17
NL1029828C2 (en) 2006-10-20
CA2577999A1 (en) 2006-03-09
BRPI0515118A (en) 2008-07-01
EA200700380A1 (en) 2007-10-26
EP1789092A2 (en) 2007-05-30
PE20060654A1 (en) 2006-08-12
WO2006024953A3 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
ECSP077281A (en) CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME
AR047928A1 (en) TETRAHYDROPIRIDOINDOL DERIVATIVES
BR0313343A (en) Use of a mixture of permeation agents, nail and periungual solutions and use of a nail and periungual solution
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
BRPI0513508A (en) insulin-oligomer conjugates, formulations and uses of these
CO6501124A2 (en) IMMUNOMODULATING POLYPEPTIDES DERIVED IS THE IL 2 AND ITS THERAPEUTIC USE IN CANCER AND IN CHRONIC INFECTIONS
PE20090605A1 (en) COMPOSITIONS OF AMMONIA PHENYLALANINE-LIASA PROCARIOTICA AND METHODS OF TREATMENT OF CANCER USING COMPOSITIONS OF THE SAME
IT1288290B1 (en) SELF-LETICULATED HYALURONIC ACID AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ARTHROPATHIES
PE20080339A1 (en) MODIFIED POLYPEPTIDES OF THE COAGULATION FACTOR IX AND USE OF THE SAME FOR TREATMENT
AR053651A1 (en) COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER
CR11648A (en) COMPOSITION UNDERSTANDING ANTIBODY THAT IS SET TO DOMAIN II OF HER2, AND ITS VARIOUS ACIDS
AR069830A1 (en) FACTOR VIII AND FACTOR OF VON WILLEBRAND MODIFIED RECOMBINANTS AND METHODS OF USE OF THE SAME
BR0308429A (en) Monocyclic Aroylpyridinones as Anti-Inflammatory Agents
CY1111177T1 (en) FAINOTHEASINE UNION FOR INJURY HEALING
EA201370006A1 (en) LOCAL PHARMACEUTICAL COMPOSITION CONTAINING FLURBIPROPHEN
AR051765A1 (en) COMPOUNDS OF MOLECULES CONJUGATED WITH A REINFORCED ACTIVITY OF CELL ABSORPTION
CY1109843T1 (en) Analogues of Vitamin D
AR077347A1 (en) IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS AND RELATED TO THEM
MX2012007225A (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue.
ECSP088242A (en) COMBINATIONS UNDERSTANDING DMXAA FOR CANCER TREATMENT
BR112015022730A2 (en) rfviii formulations, method for covalent conjugation of rfviii to a biocompatible polymer and use of rfviii in the preparation of rfviii formulation for treating hemophilia a
DOP2005000172A (en) CONJUGATES OF HUMAN GROWTH HORMONES AND POLYETHYLENGLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHOD OF USE OF THE SAME
BRPI0607844B8 (en) use of egf and ghrp-6
BR112022003751A2 (en) Hemoglobin analogues cross-linked with thiosuccinyl and methods of use and preparation thereof